In Partnership with:
4385 Stories, most recent news story added Sun May 27, 8:26 pm ET
Recent recommendations from the US Preventive Services Task Force advising elimination of routine prostate-specific antigen screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physicians, according to results of a new survey.
Gunter Lauterbach knows first-hand the benefits of prostate cancer research. Lauterbach, of Lagoon City, is a survivor. “When I was diagnosed in 2003, there weren’t a lot of options as far as treatment,” he said.[...]
Prostate-Cancer Screening: Men Should Forgo PSA Testing, Panel Advises
WASHINGTON - After lung cancer, prostate cancer is the most prevalent killer of men in the United States. So when the U.S. Preventive Services Task Force (USPSTF) recommended that men stop having a test that can tell if they have prostate cancer, it stirred up controversy in the medical community. For years, men over the age of 40 were told to get a simple blood test to see if they have prostate ...
Amid the many messages you will hear about screening for prostate cancer in the coming days, I hope these stand out: There is at best a small potential benefit from prostate cancer screening, and there are substantial known harms. We need a better test, and we need better treatment options. The panel I chair, the U.S. Preventive Services Task Force, has just issued a recommendation against ...
Should men be routinely screened for prostate cancer? This question has been asked ever since the prostate specific antigen test, or PSA, became widely available more than two decades ago.
Hundreds of motorcycles hit the pavement in Winnipeg Saturday as part of Ride for Dad - an organization that raises money for prostate cancer research and education.
SWEET HOME — A prostate cancer support group will meet from 7 to 9 p.m. Thursday, June 7, at the Jim Riggs Community Center, 878 18th Ave., Sweet Home.
URBANA, ILL. — Prostate cancer is uncommon among dogs, and when they're diagnosed with it, the outcome is never hopeful. It can be treated for a time, but never cured.
The PSA prostate-cancer test used by half of U.S. men older than 40 carries more risks than benefits and shouldn’t be used to diagnose the disease, a U.S. panel said, reaffirming its earlier advice.
DiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA.
Open slideshowKVUE-TV Austin Videos
Open slideshowFOX News Videos
Open slideshowAssociated Press Videos
Open slideshowCBS 3 Philadelphia
Open slideshowMarketwire
